CAR-T cell therapy - TC BioPharm
Latest Information Update: 20 May 2024
At a glance
- Originator Unknown
- Developer TC BioPharm
- Class CAR-T cell therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Autoimmune disorders